Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025
-
Dec 19, 2025, 09:24Zain Khalpey on A New Study Linking Low-dose Aspirin to Reduced Cancer Spread
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders